Development of novel anti-cancer autoantibody for control of pancreatic cancer

• Project/Area Number: 17K15947
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Gastroenterology
• Research Institution: Okayama University
• Principal Investigator: KAzuyuki Matsumoto 岡山大学, 大学病院, 助教 (40795027)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: RPL29 / PD-L1 / 膵臓癌 / PD-1 / FNA / 抗RPL29抗体 / 膵癌

Outline of Final Research Achievements

We evaluated the anti-RPL antibody in the serum of patients with pancreatic cancer using the ELISA method. The results showed that there was no significantly difference in the survival time between patients with high and low antibody titers. It is considered that anti-RPL antibody is not involved in the prognosis of patients with pancreatic cancer in this study.
For an additional study, we focused on PD-1 which has been clinically applied as an antibody therapeutic agent. We evaluated the relationship between the PD-L1 expression of surgical resected and FNA specimens for patients with pancreatic cancer. Of the 94 patients,11 (10%) was defined as positive on resected cancer specimens. The concordance rates for the positive and negative frequency of PD-L1 expression between resected and FNA specimens were 55% (6/11) and 99% (82/83), respectively.These results have potential utility in the field of precision medicine for patients with pancreatic cancer.

Academic Significance and Societal Importance of the Research Achievements

RPL29に対する抗体を血中に有する膵臓癌の予後が良いという過去の報告や、RPL抗原が癌や血管内皮細胞増殖に関与している既報事実はあるものの、本研究では抗RPL抗体価の違いによる生存期間の差異はなかった。治療法別にも検討をしたが、同様に生存には寄与しなかった。
PD-L1染色の検討では、超音内視鏡で採取した検体と切除検体では、感度が約５０％と低いものの、正診率は9割を超えており、今後、抗PD-L1抗体を投与する際のコンパニオン診断として有用になる可能性がある。治療効果が見込める患者への適切な投与により、治療効果の増大や、医療費の削減にもつながる可能性がある

Research Products

• [Journal Article] The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. (2019)
  • Author(s): Matsumoto K, Ohara T, Fujisawa M, Takaki A, Takahara M, Tanaka N, Kato H, Horiguchi S, Yoshida R, Umeda Y, Fushimi S, Yagi T, Matsukawa A, Okada H
  • Journal Title: J Gastroenterol. Volume: Apr 29 Issue: 11 Pages: 1019-1028
  • DOI: 10.1007/s00535-019-01586-6
  • NAID: 120006839238
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Presentation] The relationship between the PD-L1 expression of surgical resected and fine-needle aspiration specimens for patients with pancreatic cancer (2019)
  • Author(s): Kazuyuki Matsumoto, Toshiaki Ohara, Masayoshi Fujisawa, Akinobu Takaki, Masahiro Takahara, Hironari Kato, Shigeru Horiguchi, Akihiro Matsukawa, Hiroyuki Okada
  • Organizer: Digestive Disease Week 2019. AGA
  • Int'l Joint Research
• [Presentation] 膵癌におけるFNA検体と切除検体とのPD-L1発現の検討 (2019)
  • Author(s): 松本 和幸, 高木 章乃夫, 大原 利章, 藤澤 真義, 高原 政宏, 加藤 博也, 吉田 龍一, 楳田 祐三, 八木 孝仁, 松川 昭博, 岡田 裕之
  • Organizer: JDDW 2019
• [Presentation] 膵癌におけるFNA検体と切除検体とのPD-L1発現の検討 (2019)
  • Author(s): 松本 和幸, 高木 章乃夫, 大原 利章, 藤澤 真義, 高原 政宏, 加藤 博也, 吉田 龍一, 八木 孝仁, 松川 昭博, 岡田 裕之
  • Organizer: 日本内科学会 中国地方会